Report Company Directory
- CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split by GlobeNewsWire
- CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia by GlobeNewsWire
- CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting by GlobeNewsWire